ArticleThe Journal of clinical investigation2021

Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.

Eleni Panagioti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.